Investor Presentation

98 Investor presentation First six months of 2022 AD patient journey is complex and underscores key barriers to overcome for Novo Nordisk to be successful Million Significant and growing unmet need Hurdles 80 60 Novo NordiskⓇ Y Y Early symptoms dismissed as normal ageing Complex tests and limited screening/ diagnosing skills Lack of prognostic markers and simple tests No DMT options Few patients AD receiving diagnosis 40 prevalence 20 20 0 Prevalence Diagnosed Eligible patients patients MCI Mild dementia Note: MCI and Mild dementia in the graph are both due to AD. • Support healthcare system preparedness Larger number of AD patients expected to enter the system May lead to significant bottle- necks and delay to patient care Market preparation priorities Increase diagnosis rate Indicates expected invesment level Support NITs development, e.g. blood-based/digital biomarkers Increase AD education and access to screening tools for PCPs and HCP insight Evidence generation AD: Alzheimer's disease; QD: Once-daily; MCI: mild cognitive impairment; DMT: Disease-modifying treatment; PCP: primary care physicians; NITS: Non-invasive diagnostics; HCP: Healthcare professional Source: Alzheimer's Association report: 2020 Alzheimer's disease facts and figures, 2020 (16:391-460) Evidence to better understand the • impact of delaying disease progression role of neuroinflammation in disease progression

View entire presentation